| Similar Articles |
|---|
 |
The Motley Fool
January 27, 2009
Robert Steyer |
Another Angle for Fibromyalgia In the past 18 months, the FDA has approved three drugs that can be used to treat the disease. Which pharma companies will benefit?   |
The Motley Fool
September 30, 2005
Stephen D. Simpson |
Two Pharma Trees Fall The news of a phase 3 trial failure hammers both Forest Labs and Cypress Bioscience. Investors, take note. |
The Motley Fool
November 5, 2010
Brian Orelli |
Better Late Than Never for Cymbalta Eli Lilly gets an expanded approval for Cymbalta. |
The Motley Fool
June 6, 2011
Brian Orelli |
Big Pharma Tackles Lung Cancer; Biotech Helping, Too A big underserved market. |
The Motley Fool
September 30, 2010
Brian Orelli |
Avoid This Multibillion-Dollar Market It's just too crowded, but there's no doubt that psychiatric drugs are big business for some drugmakers. |
The Motley Fool
August 18, 2010
Brian Orelli |
More Pain Ahead for Eli Lilly? An advisory panel meeting tomorrow could further the company's slide. |
The Motley Fool
August 10, 2010
Ryan McBride |
Vertex's Telaprevir Clears Hurdle, Could Halve Treatment Times for Hepatitis C Study results are positive. |
The Motley Fool
August 23, 2010
Brian Orelli |
No Way to Jazz Up This Result Jazz Pharmaceuticals investors went from ecstatic to devastated in less than a week. |
The Motley Fool
December 9, 2008
Brian Orelli |
The FDA Can't See the Forest or the Trees Forest Laboratories and Cypress Bioscience are still waiting for FDA approval, but now they've got more data to prove their point. |
The Motley Fool
March 4, 2010
Brian Orelli |
A Painless Drug Deal Bristol-Myers licenses pain drug from Allergan. |
The Motley Fool
November 24, 2010
Brian Orelli |
A Manly FDA Approval Eli Lilly has something to be thankful for this week; the Food and Drug Administration approved Axiron, its testosterone replacement therapy. |
The Motley Fool
February 25, 2009
Brian Orelli |
Pfizer Doesn't Like Reruns The company drops two drugs that had made it as far as phase 3 trials. |
The Motley Fool
August 18, 2010
Brian Orelli |
No Pain Here as Jazz Shares Rocket Investors are all jazzed up about Jazz Pharmaceuticals |
The Motley Fool
January 29, 2009
Brian Orelli |
Lilly's in Need of a Pep Pill Eli Lilly's quarterly earnings report was pretty boring. Some drugs were up and others were down -- the end result was flat sales. |
The Motley Fool
October 11, 2010
Brian Orelli |
FDA Rejection, but Still Jazzed Up Sometimes, biotechs are like that. |
AskMen.com
March 2, 2003
Mike Davison |
Fibromyalgia: The Prison Of Pain Fibromyalgia, also known as fibromyalgia syndrome or FMS, is a widespread muscular and skeletal pain, and fatigue disorder affecting the fibrous tissues of the muscles, ligaments and tendons. |
The Motley Fool
September 15, 2010
Bruce V. Bigelow |
In Appeal to Cypress Bio Stockholders, Ramius Raises Buyout Offer The battle for control is heating up. |
The Motley Fool
October 22, 2009
Robert Steyer |
Nibbles Here and There at Forest Labs Forest Laboratories banks on its usual strategy of licensing and collaboration to offset generic-drug threats. |
Nurse Practitioner
April 2012
Firestone et al. |
Optimizing fibromyalgia management This article summarizes current information regarding the etiology, pathophysiology, clinical presentation, diagnostic standards, and pharmacologic and non-pharmacologic treatments necessary to successfully manage FM. |
American Family Physician
October 1, 2000 |
Information for Patients Living with Fibromyalgia What is fibromyalgia?... What causes fibromyalgia?... How does my doctor know I have fibromyalgia?... How is fibromyalgia treated?... |
Health
June 2007
Melanie Haiken |
The Best New Pain Cures?... For Women New research shows that pain can often be prevented if women use the right treatment. Here's what you should know. |
Nursing
February 2010
Daniel A. Hussar |
New Drugs 2010, PART 1 In this article, you'll learn about 16 new drugs. |
American Family Physician
October 1, 2000
Millea & Holloway |
Treating Fibromyalgia Fibromyalgia is an extremely common chronic condition that can be challenging to manage... |
Nurse Practitioner
December 2011 |
Managing pain in obese patients Obesity-related pain conditions can limit the patient's efforts at increasing activity and limit quality of life. This article will offer information on these conditions and treatment options. |
American Family Physician
February 1, 2005
Maizels & McCarberg |
Antidepressants and Antiepileptic Drugs for Chronic Non-Cancer Pain The development of newer classes of antidepressants and second-generation antiepileptic drugs has created unprecedented opportunities for the treatment of chronic pain. These drugs modulate pain transmission by interacting with specific neurotransmitters and ion channels. |
Nursing Management
March 2012
Yvonne D'Arcy |
Pain and obesity It can be a challenge to provide effective pain management for obese patients; however, a multimodal pain management regimen that combines medications and complementary techniques can help increase pain relief. |
Managed Care
October 2003
Martin Sipkoff |
Pain Management: Health Plans Need to Take Control Insurers have not focused much on chronic pain. They should. It presents a humanitarian and business opportunity. |
The Motley Fool
October 3, 2011
Harsh Chauhan |
Why This Stock Looks Like a Buy Authorization of another buyback bodes well for Cypress. |
